| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,356 | 0,430 | 15.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Mendus AB: Mendus announces initial immunological data from CADENCE and VITAL-CML indicating vididencel improves immune competence across indications | 145 | GlobeNewswire (Europe) | Vididencel-induced immune responses activate multiple compartments of the immune system based on initial samples from the ongoing CADENCE and VITAL-CML trialsThe data are consistent with earlier observations... ► Artikel lesen | |
| Mi | Mendus AB: Mendus AB Interim Report July - September 2026 | 139 | GlobeNewswire (Europe) | Transforming immunotherapy for myeloid blood cancersGrowing evidence from completed and ongoing trials indicates that vididencel stimulates the immune system in a unique way, leading to broad tumor-directed... ► Artikel lesen | |
| Di | Mendus AB: Mendus and NorthX Biologics expand collaboration to include production of memory NK cell therapies | 143 | GlobeNewswire (Europe) | Mendus and NorthX Biologics expand their collaboration to establish manufacturing of memory NK cells for therapeutic purposes, alongside the ongoing large-scale production of Mendus' lead product vididencel.The... ► Artikel lesen | |
| 05.10. | Mendus AB: Mendus announces appointment of Hans Preusting as Chief Operating Officer | 175 | GlobeNewswire (Europe) | Hans Preusting (PhD, MBA) will join the management team as COO on 5 October 2026 and, as a consequence, step down from the Mendus board, where he has been an independent member since May 2021.This appointment... ► Artikel lesen | |
| 16.09. | Mendus AB: Mendus announces initiation of the DIVA trial | 186 | GlobeNewswire (Europe) | Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced the initiation of the DIVA trial evaluating vididencel in combination... ► Artikel lesen | |
| MENDUS Aktie jetzt für 0€ handeln | |||||
| 14.09. | Mendus AB: Mendus draws under the second tranche of the Fenja Capital II A/S loan facility, extending cash runway into the second quarter of 2027 | 204 | GlobeNewswire (Europe) | Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announces that the Company will draw down SEK 16.5 million under a second... ► Artikel lesen | |
| 11.09. | Mendus AB: Mendus reports positive read-out for first stage VITAL-CML trial | 271 | GlobeNewswire (Europe) | Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced a positive read-out of the first safety and tolerability stage of... ► Artikel lesen | |
| 20.08. | Earnings Call Transkript: Mendus senkt Kosten und treibt Krebsstudien im zweiten Quartal 2026 voran | 2 | Investing.com Deutsch | ||
| 20.08. | Mendus reduziert Verlust im zweiten Quartal dank Fortschritten bei Blutkrebsstudien | 1 | Investing.com Deutsch | ||
| 20.08. | Mendus AB: Mendus Ab Interim Report April- June 2026 | 222 | GlobeNewswire (Europe) | Building momentum across myeloid blood cancers
Clinical development gathered momentum during the second quarter of 2026, broadening the positioning of vididencel in acute myeloid leukemia (AML) and... ► Artikel lesen | |
| 08.07. | Mendus AB: Mendus reports complete enrollment of the first stage of the VITAL-CML trial | 266 | GlobeNewswire (Europe) | VITAL-CML is a pivotal trial to confirm the safety and feasibility of vididencel immunotherapy in patients with suboptimal responses to current standard of care with tyrosine kinase inhibitors (TKIs)Completion... ► Artikel lesen | |
| 02.06. | Mendus AB: Mendus reports long-term progression-free survival associated with broad immune activation in high-risk ovarian cancer | 210 | GlobeNewswire (Europe) | • ALISON trial data presented at ASCO demonstrate broad immune activation and support further evaluation of vididencel in combination approaches to improve durable disease control• Five participants... ► Artikel lesen | |
| 08.05. | Mendus AB: Mendus AB Interim Report January - March 2026 | 337 | GlobeNewswire (Europe) | Start of clinical program in chronic myeloid leukemia
As part of its updated clinical strategy communicated end of 2025, Mendus is expanding clinical development of the lead product vididencel to include... ► Artikel lesen | |
| 21.04. | Mendus AB: Mendus announces first patient enrolled in the VITAL-CML trial | 390 | GlobeNewswire (Europe) | Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced that the first patient has been enrolled in the VITAL-CML trial... ► Artikel lesen | |
| 23.03. | Mendus - Agreement to advance AML programme | 989 | Edison Investment Research | Mendus has announced a new clinical collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI) to support the Phase Ib DIVA trial, evaluating lead cancer vaccine vididencel in chemo-unfit... ► Artikel lesen | |
| 13.02. | Mendus - Vididencel set for a defining year | 772 | Edison Investment Research | Mendus's FY25 results mark a strategically important year, culminating in the repositioning of lead asset vididencel in Q425. Clinical updates in acute myeloid leukaemia (AML) and ovarian cancer (OC)... ► Artikel lesen | |
| 11.02. | Mendus AB: Mendus AB Year-end Report 2025 | 313 | GlobeNewswire (Europe) | Capturing the immunotherapy opportunity in myeloid blood cancers
In the fourth quarter of 2025, Mendus presented continued positive long-term survival data of the ADVANCE II trial in acute myeloid leukemia... ► Artikel lesen | |
| 16.12.25 | Mendus AB: Report from the Extraordinary General Meeting of Mendus AB (publ) on 16 December 2025 | 412 | GlobeNewswire (Europe) | At the extraordinary general meeting (the "EGM") of Mendus AB (publ), reg. no. 556629-1786, (the "Company"), on 16 December 2025 adopted, inter alia, the following resolutions. For more detailed information... ► Artikel lesen | |
| 10.12.25 | Mendus - ASH 2025 update supports renewed strategy | 762 | Edison Investment Research | Mendus has presented incremental clinical data for vididencel at the American Society of Hematology (ASH) 67th Annual Meeting, involving long-term follow-up for the ADVANCE II trial. This study is testing... ► Artikel lesen | |
| 01.12.25 | Mendus AB: Mendus Announces Large-Scale Vididencel GMP Production Milestone in Manufacturing Alliance with NorthX Biologics | 447 | GlobeNewswire (Europe) | Mendus AB (publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced the successful establishment of large-scale GMP production of its lead product... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,70 | +0,06 % | Option auf Zeitgewinn: BioNTech investiert Millionen in möglichen Zulassungsvorsprung | Mit einem Prüfungsgutschein will BioNTech die Entscheidung der US-Arzneimittelbehörde über ein Krebsmedikament um rund vier Monate vorziehen. Damit wären frühere Umsätze möglich, doch Studienrückschläge... ► Artikel lesen | |
| EVOTEC | 2,966 | -5,06 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| BB BIOTECH | 58,60 | -0,34 % | Christian Koch, Leiter BB Biotech Team bei Bellevue Asset Management, im Interview | von Robert Jakob Moneycab.com: Herr Koch, acht bestehende Beteiligungen verkauft, zwölf neue Positionen aufgebaut, das sieht nach einer grösseren Rochade aus? Die Veränderungen spiegeln unser aktives... ► Artikel lesen | |
| MEDIGENE | 0,003 | -5,88 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| AMGEN | 422,30 | -0,05 % | Amgen Announces Positive Phase 3 Results For Dazodalibep In Sjögren's Disease | Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/... ► Artikel lesen | |
| NOVAVAX | 7,770 | +0,39 % | Novavax: Zahlen über Plan - was Anleger jetzt prüfen sollten | ||
| HEIDELBERG PHARMA | 2,010 | -2,90 % | Wo Analysten das meiste Potenzial sehen: Formycon, Heidelberg Pharma und Medios | ||
| ILLUMINA | 185,58 | -1,19 % | Illumina Inc. Bottom Line Rises In Q3 | SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) announced a profit for its third quarter that Increases, from last yearThe company's bottom line came in at $220 million, or $1.43 per share. This... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 862,00 | -0,59 % | Regeneron-Aktie: Erneute Aufwärtsbewegung nach Konsolidierung | Nach den jüngsten Quartalsergebnissen erreichte Regeneron ein neues Jahreshoch, bevor eine Konsolidierung einsetzte. Die anschließende Kurserholung hat ein höheres Tief hinterlassen, während das bisherige... ► Artikel lesen | |
| AAP IMPLANTATE | 1,420 | +3,65 % | EQS-News: aap Implantate AG: Vorstand präzisiert Prognose 2026 und gibt erstmals Ausblick auf 2027 - Ambition 2030: Umsatz von mindestens EUR 21 Mio. bei einer EBITDA-Marge von 17,5 % bis 22,5 % | EQS-News: aap Implantate AG
/ Schlagwort(e): Prognose
aap Implantate AG: Vorstand präzisiert Prognose 2026 und gibt erstmals Ausblick auf 2027 - Ambition 2030: Umsatz von mindestens... ► Artikel lesen | |
| CO.DON | 0,005 | -35,71 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| BIOXXMED | 0,800 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 30.10.2026 | The following instruments on XETRA do have their last trading day on 30.10.2026Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 30.10.2026ISIN NameDE000A41YD32 BIOXXMED AG INH O.N.DE000HLB78G8... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,278 | -1,84 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights | VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent... ► Artikel lesen | |
| INFLARX | 1,085 | +1,78 % | InflaRx im Check: Izicopan rückt vor, der Chart bleibt unter Druck | ||
| INTELLIA THERAPEUTICS | 8,830 | +0,23 % | Intellia stock price target maintained at $30 by Citizens on HAE data |